Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Op Gr: Emerging COVID-19 Research Gap & Priorities - Testing models/surveillance

McGill University

$320,000.00

An Automated Molecular Point of Care Testing Device for Rapid Detection of SARS-CoV-2 and New Variants

FY 2021-22

Summary
Since the beginning of COVID-19 pandemic in March 2020, over 130,000,000 confirmed cases and 3,000,000 deaths have been identified. The shortage of approved low cost rapid diagnostic tests has inhibited the testing of individuals with mild or hidden symptoms, facilitating viral spread the spread of the virus. In this proposal, we gather a team of experts from McGill University, Lady Davis Institute and McGill University Health Centre to address this need. Our team has already developed a testing device for molecular detection of SARS-CoV-2 RNA in a portable and quantifiable fashion with a turnaround time of 10 min. The prototype demonstrate the full cycle of sample preparation (on-chip viral RNA extraction from saliva/nasal swab and amplification) and viral RNA detection via an established RT-LAMP assay. Here, we propose a 1 year modular plan to interface our platform with a smartphone, so that it be easily operated in remote locations, validate our rapid RNA-based testing device with new SARS-CoV-2 variants, B.1.1.7 and 501Y.V2 and to investigate distribution of SARS CoV2 variants in clinical samples. We will also develop an automation approach that can potentially simplify testing of SARS-CoV-2 and new variants in remote locations, making it easier and cheaper to manufacture tests. Our aim is to provide easy access to the results of diagnostics testing in remote locations and avoid overloading hospitals and lab facilities. Overall, the potential to increase COVID-19 testing rate at a low cost will benefit the Canadian health system during the current pandemic and help prevent similar pandemics in the future.
Program
Op Gr: Emerging COVID-19 Research Gap & Priorities - Testing models/surveillance
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
448947
Name
Mahshid Sara
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Operating Grant: Emerging COVID-19 Research Gap & Priorities - Testing models/surveillance
Projecttitle
An Automated Molecular Point of Care Testing Device for Rapid Detection of SARS-CoV-2 and New Variants
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$320,000
Cihrequipment2
$0
Programname2
Op Gr: Emerging COVID-19 Research Gap & Priorities - Testing models/surveillance
Keyworddelim
Detection Of New Variants; Molecular Detection Of Sars-Cov-2; Point Of Care Diagnostics; Rna-Based Covid-19 Test
Abstract
Since the beginning of COVID-19 pandemic in March 2020, over 130,000,000 confirmed cases and 3,000,000 deaths have been identified. The shortage of approved low cost rapid diagnostic tests has inhibited the testing of individuals with mild or hidden symptoms, facilitating viral spread the spread of the virus. In this proposal, we gather a team of experts from McGill University, Lady Davis Institute and McGill University Health Centre to address this need. Our team has already developed a testing device for molecular detection of SARS-CoV-2 RNA in a portable and quantifiable fashion with a turnaround time of 10 min. The prototype demonstrate the full cycle of sample preparation (on-chip viral RNA extraction from saliva/nasal swab and amplification) and viral RNA detection via an established RT-LAMP assay. Here, we propose a 1 year modular plan to interface our platform with a smartphone, so that it be easily operated in remote locations, validate our rapid RNA-based testing device with new SARS-CoV-2 variants, B.1.1.7 and 501Y.V2 and to investigate distribution of SARS CoV2 variants in clinical samples. We will also develop an automation approach that can potentially simplify testing of SARS-CoV-2 and new variants in remote locations, making it easier and cheaper to manufacture tests. Our aim is to provide easy access to the results of diagnostics testing in remote locations and avoid overloading hospitals and lab facilities. Overall, the potential to increase COVID-19 testing rate at a low cost will benefit the Canadian health system during the current pandemic and help prevent similar pandemics in the future.
Competitiondate
202104
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mahshid, Sara; Costiniuk, Cecilia T; Liang, Chen; Reisner, Walter W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $320,000~ $0~
McGill University - $320,000 Grant (2021-22) | Canada Spends